QQ客服 官方微博 反馈留言

	Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials
	Nelson, Mark; Amaya, Gerardo; Clumeck, Nathan; da Cunha, Clovis Arns; Jayaweera, Dushyantha; Junod, Patrice; Li, Taisheng; Tebas, Pablo; Stevens, Marita; Buelens, Annemie
	2012
卷号	67期号:8页码:2020-2028
关键词	TMC278 efavirenz hepatitis hepatic safety non-nucleoside reverse transcriptase inhibitors HBV HCV
ISSN号	0305-7453
DOI	10.1093/jac/dks130
URL标识	查看原文
收录类别	SCIE
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6707359
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Nelson, Mark,Amaya, Gerardo,Clumeck, Nathan,et al. Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials[J],2012,67(8):2020-2028.
APA	Nelson, Mark.,Amaya, Gerardo.,Clumeck, Nathan.,da Cunha, Clovis Arns.,Jayaweera, Dushyantha.,...&Boven, Katia.(2012).Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials.,67(8),2020-2028.
MLA	Nelson, Mark,et al."Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials".67.8(2012):2020-2028.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。